ENDPOINTS

FDA's Prasad details decision to pause chikungunya vaccine in seniors

The FDA and CDC's decision last month to pause administering Valneva's live-attenuated chikungunya vaccine in patients 60 and older was meant to provide more time to examine a potential causal relationship between the vaccine and ...

Jun 5, 2025 - 16:24
 0
FDA's Prasad details decision to pause chikungunya vaccine in seniors
The FDA and CDC's decision last month to pause administering Valneva's live-attenuated chikungunya vaccine in patients 60 and older was meant to provide more time to examine a potential causal relationship between the vaccine and ...
Read More

Tags:

Previous Article

Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis

Next Article

High-quality OLED displays now enabling integrated thin and multichannel audio

Related Posts

Novo Nordisk CEO to step down, timeline for successor unknown

Novo Nordisk CEO to step down, timeline for successor u...

May 16, 2025  0

CHMP clears path for GSK’s Blenrep relaunch, recommends four other drugs 

CHMP clears path for GSK’s Blenrep relaunch, recommends...

May 23, 2025  0

Analyzing the Endpoints 100; ‘Most favored nation’ targets revealed; Biotech slump makes leases a liability; and more

Analyzing the Endpoints 100; ‘Most favored nation’ targ...

May 24, 2025  0